WIN Consortium

Name

WIN Consortium

Legal name

Worldwide Innovative Network (WIN) Association

Website

https://winconsortium.org

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Precision Oncology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Voluntary Health Organizations (813212), Professional Organizations (813920)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)

Keywords

• Precision oncology research
• Clinical trial collaboration
• Cancer genomic profiling
• Biomarker discovery
• Transcriptomic profiling

Headquarters

HQ city

Villejuif

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Institutional Membership Fees: WIN Consortium operates as a non-profit, non-governmental organization funded through membership contributions from 38 institutional members including academic cancer centers, life science companies, biotech organizations, and technology companies. Membership fees support consortium operations and global clinical trial activities.
2. Research Grants and Philanthropy: Funded by organizations such as ARC Fondation for cancer research (France), pharmaceutical partners who donate drugs for trials (e.g., Pfizer Inc.), and other cancer research foundations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

WIN Consortium is a global non-profit research consortium that designs and conducts collaborative clinical trials and research projects in precision oncology. Its core offerings include the WINTHER personalized medicine trial (RNA + DNA profiling), the SPRING lung cancer tri-therapy trial, the Digital Display Precision Predictor (DDPP) biomarker model, and the annual WIN Symposia. The consortium serves academic cancer centers, pharmaceutical and biotech companies, and technology firms through membership-based participation in global research.

Product overview

WIN Consortium is a non-profit, non-governmental research organization focused on accelerating precision oncology through global clinical trials and collaborative research. The consortium does not offer commercial products or services; instead, it conducts collaborative studies including WINTHER (genomic/transcriptomic profiling trial), SPRING (lung cancer tri-therapy trial), and DDPP (Digital Display Precision Predictor biomarker model). WIN also organizes annual symposia for knowledge exchange among its global member institutions.

Differentiator

Problem solved

Functional benefit

Products and services

• WIN Consortium Membership
• Digital Display Precision Predictor (DDPP)
• SPRING Clinical Trial
• WINTHER Clinical Trial WIN's first global personalized medicine clinical trial, demonstrating that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling alone. Enrolled 101 patients with various metastatic cancers, exploring transcriptomic and genomic profiling data with both tumor and normal organ-matched tissue. Results published in Nature Medicine.
• WIN Symposia Series Annual scientific symposia bringing together hundreds of global leaders in precision oncology to exchange ideas, share research findings, and engage new member institutions. ASCO-endorsed for 14 consecutive years. WIN 2024 (Abu Dhabi) had 450+ attendees from approximately 30 countries. WIN 2025 is featured as the Oncology Track of the APM Annual Conference in Philadelphia.

Quantifiable outcome

• RNA profiling with DNA testing matches more patients to personalized therapies than DNA profiling alone (WINTHER trial, Nature Medicine)
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and major.

• SWOG Cancer Research NetworkcoreStrategic or Co-development Partner · 9 December 2025SWOG Cancer Research Network, one of the five network groups in NCI's National Clinical Trials Network (NCTN), has joined WIN Consortium. This alliance combines two organizations with deeply aligned missions to accelerate progress against cancer. SWOG will collaborate with WIN and its member institutions to advance precision medicine and biomarker-driven research, aiming to reduce the cost of cancer care while improving clinical effectiveness globally.
• Advancing Precision Medicine (APM) ConferencemajorGTM or Marketing Partner · 3 October 2025WIN Symposium 2025 featured as the Oncology Track of the APM Annual Conference held at Pennsylvania Convention Center, Philadelphia. This partnership positions WIN as a major track within a larger precision medicine conference, extending reach to broader audience including multi-omics and disease-specific tracks.
• TempuscoreTechnology or Integration · 4 July 2025WIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East. Tempus deploys its comprehensive molecular profiling platform—including solid tumor (xT/xR) and liquid biopsy (xF)—to analyze tumor biology longitudinally in the study. The study focuses on understanding disease progression and treatment response with emphasis on identifying novel biomarkers and ctDNA for MRD monitoring.
• Journal of Immunotherapy and Precision Oncology (JIPO)majorGTM or Marketing Partner · 28 December 2024JIPO and WIN renewed their cooperation to cover the WIN 2024 symposium. JIPO publishes the symposium abstracts. Dr. Vladimir Lazar, WIN Chief Scientific and Operating Officer, was appointed to the JIPO Editorial Board. This partnership provides peer-reviewed publication outlet for WIN research and enhances visibility of consortium activities.
• Burjeel HoldingsmajorStrategic or Co-development Partner · 1 March 2024WIN Consortium partnered with Burjeel Holdings for the WIN 2024 Symposium held at Rosewood Hotel in Abu Dhabi, UAE. Theme was 'Precision and Molecular Oncology: Caring for Patients and Future Generations.' Burjeel's Group Chief Research Officer, Khaled Musallam, served as Symposium Chairperson. The partnership brought together 450+ clinicians, researchers, and industry professionals from 30 countries.
• Pfizer Inc.coreStrategic or Co-development Partner · 1 January 2015Pfizer Inc. donated drugs for the WIN SPRING clinical trial. The pharmaceutical partnership enabled the landmark tri-therapy clinical trial exploring combination targeted drug strategies in first-line advanced/metastatic non-small cell lung cancer.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Stand Up To Cancer: Charitable program funding collaborative translational cancer research including precision oncology teams. Comparable mission of accelerating breakthrough cancer therapies through cross-institution collaboration, but functions primarily as a funder rather than a trial operator.

Regional players

• Cancer Research UK: U.K.-headquartered cancer research charity funding translational and clinical research. Adjacent in mission of accelerating precision oncology research and trial support, but U.K.-centric rather than globally distributed.

Direct peers

• NRG Oncology: NCI NCTN group running biomarker-driven oncology clinical trials across U.S. and international sites. Comparable as a multi-institutional oncology research network running Phase I-III trials with academic and pharma partners.
• European Organisation for Research and Treatment of Cancer (EORTC): Europe-headquartered cooperative group conducting multi-center oncology clinical trials with global site participation. Directly comparable as a non-profit, multi-country precision oncology trial network with membership model similar to WIN.
• SWOG Cancer Research Network: One of NCI's five NCTN groups running multi-center oncology clinical trials. Directly comparable as a collaborative clinical trials network, and now an actual WIN Consortium partner following the December 2025 alliance.
• Alliance for Clinical Trials in Oncology: NCI NCTN group running oncology trials across U.S. academic centers. Comparable multi-institutional oncology trial network structure with shared membership and study design model.
• ECOG-ACRIN Cancer Research Group: NCI NCTN group conducting precision medicine and biomarker-driven cancer trials. Comparable as a similarly structured collaborative oncology research consortium with multi-institutional trial design and execution.

Broad incumbents

• American Association for Cancer Research (AACR): Large professional society advancing cancer research including precision oncology, publishing flagship journals and running scientific conferences. Overlapping scientific and convening role with WIN Symposia, but broader non-trial scope.
• American Society of Clinical Oncology (ASCO): Leading oncology professional society that has endorsed WIN Symposia for 14 consecutive years. Comparable as a global oncology convening and standards-setting body, though it is a professional society rather than a trial-conducting consortium.

Others

• Foundation for the National Institutes of Health (FNIH): U.S. nonprofit that manages public-private biomedical research partnerships for NIH including oncology initiatives. Comparable as an enabling, multi-stakeholder precision research convener, but does not itself run patient trials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/WIN_Consortium

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WIN Consortium